Cases & Investigations
Latest Case News
Xyrem (Sodium Oxybate) Antitrust Litigation – FEBRUARY 22, 2021
Judge Lucy H. Koh of the United States District Court of the Northern District of California appointed the Joseph Saveri Law Firm to serve on the Plaintiff’s Steering Committee.
EpiPen Price-Fixing Litigation – DECEMBER 16, 2020
In a three-page order, U.S. District Judge Daniel D. Crabtree said he reluctantly agrees that the upcoming trial, which was set to begin April 13, 2021, and was expected to last up to seven weeks, must be pushed back in light of the COVID-19 pandemic. “The court remains hopeful that conditions will improve and that […]
Invisalign Antitrust Litigation – DECEMBER 10, 2020
U.S. District Court Judge Vince Chhabria indicated at a hearing that he will likely reject a bid by the maker of Invisalign to dismiss claims it violated antitrust laws to take over the market for clear aligners and the mouth scanners used to make them, saying dentists had stated their claims with enough particularity for […]
Prosecuting Cases in Federal and State Courts Throughout the United States
The Joseph Saveri Law Firm handles antitrust cases, class actions, and complex litigation in federal and state courts throughout the United States. Prominent past and current cases include representing plaintiffs in a:
- Anti-poaching suit against tech leaders Apple, Adobe, Google, Intel, Pixar, Intuit, Lucasfilm, and others;
- Antitrust price-fixing suit against Cipro drug manufacturers resulting in a record $399 class recovery;
- Antitrust price-fixing suit against 22 manufacturers of aluminum, tantalum, and film capacitors in which favorable settlements to date have been reached against seven defendants;
- Suit by Former Elite Profession Mixed Martial Arts Fighters’ (MMA) against Ultimate Fighting Championship, which is charged with illegally acquiring and maintaining monopoly and monopsony power over MMA fighters;
- Suit against leading providers of global distribution system (GDS) technology for imposing unlawful contractual constraints that remove the airlines’ leverage to negotiate lower GDS fees and to develop alternative technologies; and
- An illegal reverse payment suit against three Lidoderm drug manufacturers and their subsidiaries for entering into an illegal reverse pay agreement, forcing companies and consumers to pay higher prices for Lidoderm.